{"id":"adjunct-brexpiprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Restlessness"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brexpiprazole modulates dopaminergic and serotonergic neurotransmission through partial agonism at D2 and 5-HT1A receptors. When used adjunctively with antidepressants, it enhances therapeutic response in major depressive disorder by fine-tuning monoamine signaling. This mechanism differs from typical antipsychotics by providing activity modulation rather than receptor blockade.","oneSentence":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, used as an adjunctive treatment to enhance antidepressant efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:51.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of major depressive disorder in adults"}]},"trialDetails":[{"nctId":"NCT01942733","phase":"PHASE3","title":"Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-09","conditions":"Sleep Disturbances","enrollment":44},{"nctId":"NCT01944969","phase":"PHASE3","title":"Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Major Depressive Disorder","enrollment":26},{"nctId":"NCT01837797","phase":"PHASE3","title":"Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2013-04","conditions":"Major Depressive Disorder","enrollment":129},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT01987960","phase":"PHASE3","title":"Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2013-12","conditions":"Post-traumatic Stress Disorder, PTSD","enrollment":417},{"nctId":"NCT01942785","phase":"PHASE3","title":"Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Major Depressive Disorder, Irritability","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":129,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjunct brexpiprazole","genericName":"Adjunct brexpiprazole","companyName":"H. Lundbeck A/S","companyId":"h-lundbeck-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, used as an adjunctive treatment to enhance antidepressant efficacy. Used for Adjunctive treatment of major depressive disorder in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}